Shanghai Henlius Biotech, Inc. announced that at the EGM held on July 28, 2022 approved the appointment of Mr. Deyong Wen as a non-executive director of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | +4.67% | +35.54% |
05-24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
05-24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.54% | 1.31B | |
-2.50% | 90.28B | |
-1.97% | 39.5B | |
-15.47% | 31.71B | |
+61.28% | 26.41B | |
-22.81% | 14.34B | |
-8.82% | 12.89B | |
-11.77% | 11.8B | |
-45.97% | 10.95B | |
+3.30% | 8.85B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Shanghai Henlius Biotech, Inc. Appoints Deyong Wen as a Non-Executive Director